Treatment for CAEBV
| Patient . | Acyclovir or valacyclovir . | Steroids . | Cyclosporine . | Azathioprine . | IFN-α . | IVIG . | Rituximab . | Cytotoxic chemotherapy . | Other . |
|---|---|---|---|---|---|---|---|---|---|
| Unknown whether B-, T-, or NK-cell disease | |||||||||
| 1 | + | + | Desciclovir, plasmapheresis | ||||||
| 2 | + | + | + | + | Cy | ||||
| 4 | + | + | |||||||
| 5 | + | + | Cy | Splenectomy | |||||
| B-cell disease | |||||||||
| 3 | + | + | + | + | + | Cy, Vin, Adria | Splenectomy | ||
| 6 | + | + | + | + | + | MTX, Vin | IFN-γ, 2-chlorodeoxyadenosine, splenectomy | ||
| 7 | + | + | + | + | Cy, MTX, Vin | ||||
| 8 | + | + | + | ||||||
| 9 | + | + | + | + | + | Cy, AraC, VP16 | IFN-β, ATG, splenectomy, allogeneic HSCT | ||
| 11 | + | + | + | + | Ganciclovir, plasmapheresis, splenectomy | ||||
| 12 | + | + | + | + | EPOCH | Bortezomib, autologous EBV-specific cytotoxic T cells followed by allogeneic HSCT | |||
| 13 | + | + | EPOCH-R, Cy, Flu | Bortezomib/ganciclovir, allogeneic HSCT | |||||
| 14 | + | Autologous EBV LCL-specific and LMP 1/2-specific cytotoxic T cells, lenalidomide | |||||||
| 16 | + | + | + | EPOCH-R | Allogeneic HSCT | ||||
| 17 | + | + | + | EPOH, MTX | Autologous EBV-specific cytotoxic T cells followed by allogeneic HSCT | ||||
| T-cell disease | |||||||||
| 10 | + | + | Splenectomy | ||||||
| 15 | CHOEP, hyper CVAD, MTX | High-dose cytarabine with L-asparaginase, allogeneic HSCT | |||||||
| 18 | + | + | + | + | VP16 | Syngeneic HSCT | |||
| NK-cell disease | |||||||||
| 19 | Autologous EBV-specific cytotoxic T cells followed by allogeneic HSCT |
| Patient . | Acyclovir or valacyclovir . | Steroids . | Cyclosporine . | Azathioprine . | IFN-α . | IVIG . | Rituximab . | Cytotoxic chemotherapy . | Other . |
|---|---|---|---|---|---|---|---|---|---|
| Unknown whether B-, T-, or NK-cell disease | |||||||||
| 1 | + | + | Desciclovir, plasmapheresis | ||||||
| 2 | + | + | + | + | Cy | ||||
| 4 | + | + | |||||||
| 5 | + | + | Cy | Splenectomy | |||||
| B-cell disease | |||||||||
| 3 | + | + | + | + | + | Cy, Vin, Adria | Splenectomy | ||
| 6 | + | + | + | + | + | MTX, Vin | IFN-γ, 2-chlorodeoxyadenosine, splenectomy | ||
| 7 | + | + | + | + | Cy, MTX, Vin | ||||
| 8 | + | + | + | ||||||
| 9 | + | + | + | + | + | Cy, AraC, VP16 | IFN-β, ATG, splenectomy, allogeneic HSCT | ||
| 11 | + | + | + | + | Ganciclovir, plasmapheresis, splenectomy | ||||
| 12 | + | + | + | + | EPOCH | Bortezomib, autologous EBV-specific cytotoxic T cells followed by allogeneic HSCT | |||
| 13 | + | + | EPOCH-R, Cy, Flu | Bortezomib/ganciclovir, allogeneic HSCT | |||||
| 14 | + | Autologous EBV LCL-specific and LMP 1/2-specific cytotoxic T cells, lenalidomide | |||||||
| 16 | + | + | + | EPOCH-R | Allogeneic HSCT | ||||
| 17 | + | + | + | EPOH, MTX | Autologous EBV-specific cytotoxic T cells followed by allogeneic HSCT | ||||
| T-cell disease | |||||||||
| 10 | + | + | Splenectomy | ||||||
| 15 | CHOEP, hyper CVAD, MTX | High-dose cytarabine with L-asparaginase, allogeneic HSCT | |||||||
| 18 | + | + | + | + | VP16 | Syngeneic HSCT | |||
| NK-cell disease | |||||||||
| 19 | Autologous EBV-specific cytotoxic T cells followed by allogeneic HSCT |
Adria indicates adriamycin; AraC, cytarabine; ATG, antithymocyte globulin; CHOEP, cyclophosphamide-doxorubicin-vincristine-etoposide-prednisolone; CTL, cytotoxic T lymphocyte; Cy, cyclophosphamide; EPOCH, etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin; EPOCH-R, EPOCH-rituximab; Flu, fludarabine; EPOH, etoposide-prednisone-vincristine-doxorubicin; HSCT, hematopoietic stem cell transplantation; hyperCVAD, cyclophosphamide-vincristine-doxorubicin-dexamethasone; IVIG, intravenous immunoglobulin; LCL, lymphoblastoid cell line (EBV-transformed B cell line); LMP, latent membrane protein; MTX, methotrexate; NK, natural killer; Vin, vincristine; and VP16, etoposide.